MediciNova Inc

NASDAQ MNOV

Data sourced from

and

Download Data

MediciNova Inc Non-current Liabilities to Total Liabilities Ratio 5 year CAGR for the quarter ending March 31, 2024: -21.58%

MediciNova Inc Non-current Liabilities to Total Liabilities Ratio 5 year CAGR is -21.58% for the quarter ending March 31, 2024, a -8.82% change year over year. The total non-current liabilities to total liabilities ratio measures the proportion of a company's non-current liabilities to its total liabilities. It is calculated by dividing the total non-current liabilities by the total liabilities. This ratio provides insights into the composition of a company's liabilities and the extent to which it relies on long-term debt and obligations. A higher ratio indicates a greater reliance on non-current liabilities, suggesting potential long-term financial commitments and increased financial risk. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

MediciNova Inc Non-current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2023 was 0.20, a -7.36% change year over year.
MediciNova Inc Non-current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2022 was 0.22, a -56.97% change year over year.
MediciNova Inc Non-current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2021 was 0.51, a -3.96% change year over year.
MediciNova Inc Non-current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2020 was 0.53, a -12.91% change year over year.

NASDAQ: MNOV

MediciNova Inc

CEO	Dr. Yuichi Iwaki M.D., Ph.D.
IPO Date	Feb. 8, 2005
Location	United States
Headquarters	4275 Executive Square, La Jolla, CA, United States, 92037
Employees	13
Sector	Healthcare
Industry	Biotechnology

Description

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Key trends